Drugs / SCH 721015
SCH 721015
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01162785 | Apr 2011 → Nov 2016 | urinary bladder cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01119664 | Apr 2010 → Oct 2013 | mesothelioma | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 1 | NCT01212367 | Feb 2009 → May 2015 | malignant pleural mesothelioma | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00536588 | Sep 2006 → Aug 2009 | urinary bladder neoplasm | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCH 721015 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01119664 ↗ |
| Known as | Ad.hIFN-a2b | “A Pilot Study of Repeated Dose Intrapleural Adenoviral-Mediated Interferon-Alpha (SCH 721015, Ad.hIFN-a2b) Gene Transfer for Malignant Pleural Mesothelioma” NCT01212367 ↗ |
| Known as | Ad.hIFN-alpha 2b | “The purpose of the new study is to determine the safety of administrating intrapleural SCH 721015 (Ad.hIFN-alpha 2b) in combination with chemotherapy for the management of...” NCT01119664 ↗ |
| Known as | Ad.hIFN-α | “Ad.hIFN-α (SCH 721015, adenoviral-mediated interferon alpha) is a replication-defective recombinant adenoviral vector containing the human interferon-alpha (hIFN-alpha) gene.” NCT01212367 ↗ |
| Known as | Ad.IFNalpha | “The most recent trial of IP Ad.IFNalpha (SCH 721015) at a dose of 3e11 viral particles (vp) given three days apart was safe and well tolerated, and showed high levels of IFN in...” NCT01119664 ↗ |
| Route | Other | “intrapleural SCH 721015 (Ad.hIFN-alpha 2b)” NCT01119664 ↗ |